BGIM
REGN icon

Brandywine Global Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Brandywine Global Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$17.8M Buy
+23,076
New +$15.7M 0.12% 167
2023
Q1 		– Sell
-95,740
Closed -$69.1M – 751
2022
Q4 		$69.1M Buy
95,740
+8,191
+9% +$6.04M 0.54% 43
2022
Q3 		$60.3M Sell
87,549
-2,203
-2% -$1.39M 0.56% 44
2022
Q2 		$53.1M Sell
89,752
-3,581
-4% -$2.33M 0.46% 61
2022
Q1 		$65.2M Sell
93,333
-3,327
-3% -$2.1M 0.48% 52
2021
Q4 		$61M Sell
96,660
-10,656
-10% -$6.55M 0.44% 58
2021
Q3 		$64.9M Buy
107,316
+39,126
+57% +$24.3M 0.49% 47
2021
Q2 		$38.1M Buy
68,190
+10,745
+19% +$5.44M 0.28% 89
2021
Q1 		$27.2M Sell
57,445
-66,521
-54% -$32.4M 0.2% 131
2020
Q4 		$59.9M Buy
123,966
+107,945
+674% +$58.3M 0.5% 43
2020
Q3 		$8.97M Buy
+16,021
New +$9.71M 0.09% 213

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Brandywine Global Investment Management's REGN Position: Q4 2025 in Review

Brandywine Global Investment Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2025: 23,076 shares worth $17.8M. The stake represents 0.12% of the portfolio and ranks #167 among its holdings. This is a return to the name: Brandywine Global Investment Management previously reported a position in REGN as recently as Q4 2022.

Brandywine Global Investment Management first reported a position in REGN in Q3 2020 and has held it in 11 quarters since. The position peaked at $69.1M in Q4 2022. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Brandywine Global Investment Management held 23,076 shares of Regeneron Pharmaceuticals worth $17.8M as of Q4 2025.
  • Regeneron Pharmaceuticals was a new Brandywine Global Investment Management position in Q4 2025.
  • Regeneron Pharmaceuticals made up 0.12% of Brandywine Global Investment Management's portfolio in Q4 2025, its #167 holding.
  • Brandywine Global Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2020 and has held it in 11 quarters since.
  • Brandywine Global Investment Management's Regeneron Pharmaceuticals position peaked at $69.1M in Q4 2022.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Brandywine Global Investment Management's 13F filing for Q4 2025, filed 11 Feb 2026.